Products for Research Use Only
RegisterLogin

MKC8866

CAT: 0804-HY-104040-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-104040-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
MKC8866, a salicylaldehyde analog, is a potent, selective IRE1 RNase inhibitor with an IC50 of 0.29 μM in human vitro. MKC8866 strongly inhibits Dithiothreitol-induced X-box-binding protein 1-spliced (XBP1s) expression with an EC50 of 0.52 μM and unstresses RPMI 8226 cells with an IC50 of 0.14 μM[1]. MKC8866 inhibits IRE1 RNase in breast cancer cells leading to the decreased production of pro-tumorigenic factors and it can inhibits prostate cancer (PCa) tumor growth[2].
CAS Number
1338934-59-0
Product Name Alternative
Orin1001
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
IRE1
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/IRE-1_alpha__inhibitor_1.html
Concentration
10mM
Purity
99.95
Solubility
DMSO : 6.67 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=CC1=C(O2)C(C(C)=C(CC(N3CCOCC3)=O)C2=O)=CC(OC)=C1O
Molecular Formula
C18H19NO7
Molecular Weight
361.35
Precautions
H302, H315, H319, H335
References & Citations
[1]Sheng X, et al. IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling. Nat Commun. 2019 Jan 24;10 (1) :323.|[2]Logue SE, et al. Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy. Nat Commun. 2018 Aug 15;9 (1) :3267.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2

Alternative Products

CatalogName
MBS5755005MKC8866
A19523-500MKC8866 500mg
A19523-100MKC8866 100mg
A19523-10MKC8866 10mg
A19523-1MKC8866 1mg
A19523-25MKC8866 25mg
A19523-50MKC8866 50mg
A19523-5MKC8866 5mg

Popular Products